Despite conditions of systemic inflammation, the chronic proliferation of JAK2 V617F-positive PV is sustained over decades with relatively low cumulative incidence of blast transformation (to AML) and fibrotic progression to post-PV myelofibrosis (post-PV MF, [22,73]). The gene discussed is JAK2; the disease is myelofibrosis.